Itaspor Capsule contains Itraconazole 100 mg, an antifungal agent belonging to the triazole class, indicated for the treatment of various fungal infections. Itraconazole exerts its effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itaspor is primarily used in the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and dermatophytosis. The capsule formulation allows for oral administration, ensuring adequate bioavailability and tissue penetration. Itaspor should be used as directed by a healthcare professional, with dosage adjusted according to the severity and type of infection. Caution is advised in patients with hepatic impairment, as itraconazole is extensively metabolized by the liver and may cause hepatotoxicity. Potential drug interactions should be carefully assessed due to itraconazole’s inhibition of cytochrome P450 enzymes, which can alter the metabolism of concomitant medications. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function and clinical response is recommended during therapy. Itaspor Capsule offers an effective therapeutic option for managing fungal infections when used appropriately under medical supervision.